Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Brazilian Reality of Diffuse Large B-Cell Lymphoma (BRA - DLBCL): A Multicenter Retrospective Study

Blood (2024) 144 (Supplement 1): 7725.

https://doi.org/10.1182/blood-2024-206112

Published: 2024

Journal Articles

Golseek-2: A Phase 2 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma

Jose C. Villasboas Bisneto, Pier Luigi Zinzani, Andrew J. Davies, Robert Kridel, Guilherme Fleury Perini, Parth Rao, Joanna Mikita-Geoffroy, Akshay Sudhindra, Charalambos Andreadis

Blood (2024) 144 (Supplement 1): 4422.2.

https://doi.org/10.1182/blood-2024-203181

Published: 2024

Journal Articles

Selection of CUT-Off Points for Prognostic Biomarkers in Lymphoma Using Restricted Cubic Splines: Experience of the Grupo De Estudio De Linfoproliferativos De Latinoamérica (GELL) in a Cohort of Diffuse Large B-Cell Lymphoma Patients

Blood (2024) 144 (Supplement 1): 6452.

https://doi.org/10.1182/blood-2024-198823

Published: 2024

Journal Articles

Dose-Response Relationship between Inflammatory Biomarkers and Overall Survival Using Restricted Cubic Splines: Experience of the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL) in a Cohort of Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 6474.

https://doi.org/10.1182/blood-2024-209615

Published: 2024

Journal Articles

Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study

Julio C. Chavez, Guilherme Fleury Perini, Loretta Nastoupil, Judit Mészáros Joergensen, Pierre Bories, Bijou Fontanet, Pier Luigi Zinzani, Javier Munoz, Daniel Morillo Giles, Cecilia Carpio, Abel Costa, Won Seog Kim, Parth Rao, Bérengère de Moucheron, Yang Gang, Carla Guarinos, Akshay Sudhindra, Michael Pourdehnad, Jean-Marie Michot

Blood (2024) 144 (Supplement 1): 3018.

https://doi.org/10.1182/blood-2024-203131

Published: 2024

Journal Articles

The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)

Thais Fischer, Eliana Miranda, Juliana Pereira, Guilherme Duffles, Jamila Vaz Tavarez, Nelson S Castro, Rodrigo Santucci, Danielle Leão Cordeiro De Farias, Sergio Brasil, Claudio G Macedo, Carolina Colaco, Renata Lyrio R Baptista, Karin Z Cecyn, Davimar Bortucchi, Gilnara Fontinele Silva, Samir Nabhan, Patricia Giacon, Rony Schaffel, Natalia Pin Chuen Zing, Frederico Lisboa Nogueira, Ademar Dantas Cunha, Diego Vila Cle, Jose D Tadeu, Vera Figueiredo, Mateus Dalló Dal Pont, Rafael Gaiolla, Nelson Hamerschlak, Eduardo Flavio Oliveira Ribeiro, Abrahão Elias Hallack Neto, Maria Almeida Dias, Yung Gonzaga, Yana S Rabelo, Larissa Lane Teixeira, Guilherme Fleury Perini, Milene Matedi, Priscilla Cury, Henry Idrobo, Denisse Castro, Brady Beltran, Daniel J Enriquez, Jule F Vasquez, Claudia Roche, Daniel Artiles, Fabiola Valverte, Luis Mario Villela Martinez, Ana Carolina Oliver, Laura Korin, Camila Peña, Macarena Roa, Maria Alejandra Torres, Seisha Alana von Glasenapp, Alfredo Quiroz, Cesar Samanez-Figari, Rosa Oliday Rios Jimenez, Sally Paredes, Casey Bermack, Kelly Meza, Bryan Valcarcel, Carmino A Souza, Luis Malpica, Carlos Chiattone

Blood (2024) 144 (Supplement 1): 1692.

https://doi.org/10.1182/blood-2024-211164

Published: 2024

Journal Articles

Using Polatuzumab Plus Chemotherapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Study from the Grupo De Estudio De Linfoproliferativos De Latinoamerica (GELL)

Blood (2024) 144 (Supplement 1): 1718.

https://doi.org/10.1182/blood-2024-211584

Published: 2024

Journal Articles

Primary CNS Lymphoma in Latin America: A Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL) Survey in 80 Cancer Centers in Latin America

Blood (2023) 142 (Supplement 1): 2422.

https://doi.org/10.1182/blood-2023-190477

Published: 2023

Journal Articles

Validating the Halp Score (Hemoglobin,Albumin, Lymphocytes, and Platelets) and the Neutrophil/Lymphocyte Ratio ( NLR ) As Prognostic Factors for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. Retrospective Analysis By the Grupo De Estudio De Latino America De Linfoproliferativos (GELL)

Blood (2023) 142 (Supplement 1): 1757.

https://doi.org/10.1182/blood-2023-188265

Published: 2023

Journal Articles

Real-World Data on the Clinical Features, Therapy Patterns and Outcomes of 651 Elderly Patients with Diffuse Large B-Cell Lymphoma in Latin America: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Blood (2023) 142 (Supplement 1): 1748.

https://doi.org/10.1182/blood-2023-187049

Published: 2023

Journal Articles

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Pier Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Fogliatto, A. Martin Garcia-Sancho, Beth Christian, Zafer Gulbas, Muhit Özcan, Guilherme Fleury Perini, Herve Ghesquieres, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand

Blood (2023) 142 (2): 141–145.

https://doi.org/10.1182/blood.2022019340

Published: 2023

Journal Articles

Diffuse Large B-Cell Lymphoma (DLBCL) in the Elderly: Real World Experience in Latin America. A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Blood (2022) 140 (Supplement 1): 6697–6698.

https://doi.org/10.1182/blood-2022-162389

Published: 2022

Journal Articles

Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Blood (2022) 140 (Supplement 1): 6708–6710.

https://doi.org/10.1182/blood-2022-168165

Published: 2022

Journal Articles

Evolution of Treatment Patterns and Prognostic Biomarkers in Latin American Patients with Chronic Lymphocytic Leukemia: A Study By the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Blood (2022) 140 (Supplement 1): 10918–10920.

https://doi.org/10.1182/blood-2022-168276

Published: 2022

Journal Articles

Does Prompt Access to Healthcare Impact the Outcomes of Hodgkin Lymphoma? a Comparison between Public and Private Patients Sharing the Same Infrastructure

Carolina C P Feres, Larissa LC Teixeira, Leonardo Javier Arcuri, Gabriela Amaral Vieira, Carolina Leme de Moura Pereira, Nelson Hamerschlak, Guilherme Fleury Perini

Blood (2022) 140 (Supplement 1): 3707–3708.

https://doi.org/10.1182/blood-2022-170514

Published: 2022

Journal Articles

Updated Analysis Confirms Sustained Poor Prognosis of COVID-19 in Patients with Lymphoma in Latin America: A Cohort of 160 Patients from Gell

Blood (2021) 138 (Supplement 1): 2520.

https://doi.org/10.1182/blood-2021-153875

Published: 2021

Journal Articles

Biological and Classical Prognostic Factors with Impact on Overall Survival in Patients with Early Stage (I/II) Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Blood (2021) 138 (Supplement 1): 2516.

https://doi.org/10.1182/blood-2021-152724

Published: 2021

Journal Articles

PET-CT Quantitative Parameter Delta Suvmax As a Predictor of Early Relapse in Patients with Difuse Large B-Cell Lymphoma

Carolina Feres, Guilherme Fleury Perini, Carolina Leme de Moura Pereira, Larissa Lane Cardoso Teixeira, Mariana Nassif Kerbauy, Jackson Alex Barbosa, Denise Cunha Pasqualin, Leonardo Javier Arcuri, Nelson Hamerschlak

Blood (2021) 138 (Supplement 1): 4580.

https://doi.org/10.1182/blood-2021-153615

Published: 2021

Journal Articles

Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Pier Luigi Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, Krimo Bouabdallah, Jan Waleswski, Alejandro Majlis, Laura Fogliatto, Alejandro Martin Garcia-Sancho, Beth Christian, Zafer Gulbas, Muhit Özcan, Guilherme Fleury Perini, Gilles Salles, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand

Blood (2021) 138 (Supplement 1): 306.

https://doi.org/10.1182/blood-2021-148082

Published: 2021

Journal Articles

A Simplified Novel Prognostic Score to Predict Early Mortality and Disease Progression in Patients with Aggressive Adult T-Cell Leukemia/Lymphoma

Bryan Valcarcel, Denisse Castro, Daniel J Enriquez, Camila Peña, Henry Idrobo, Lorena Fiad, Maria Prates, Sally Rose Paredes, Marialejandra Alejandra Torres Viera, Guilherme Fleury Perini, Jorge J. Castillo, Luis Villela, Brady E Beltran, Juan Carlos Ramos, Luis Malpica-Castillo

Blood (2021) 138 (Supplement 1): 1404.

https://doi.org/10.1182/blood-2021-151278

Published: 2021

NARROW

Brazilian Reality of Diffuse Large B-Cell Lymphoma (BRA - DLBCL): A Multicenter Retrospective Study

Golseek-2: A Phase 2 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma

Selection of CUT-Off Points for Prognostic Biomarkers in Lymphoma Using Restricted Cubic Splines: Experience of the Grupo De Estudio De Linfoproliferativos De Latinoamérica (GELL) in a Cohort of Diffuse Large B-Cell Lymphoma Patients

Dose-Response Relationship between Inflammatory Biomarkers and Overall Survival Using Restricted Cubic Splines: Experience of the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL) in a Cohort of Diffuse Large B-Cell Lymphoma

Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study

The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)

Using Polatuzumab Plus Chemotherapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Study from the Grupo De Estudio De Linfoproliferativos De Latinoamerica (GELL)

Primary CNS Lymphoma in Latin America: A Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL) Survey in 80 Cancer Centers in Latin America

Real-World Data on the Clinical Features, Therapy Patterns and Outcomes of 651 Elderly Patients with Diffuse Large B-Cell Lymphoma in Latin America: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Diffuse Large B-Cell Lymphoma (DLBCL) in the Elderly: Real World Experience in Latin America. A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Evolution of Treatment Patterns and Prognostic Biomarkers in Latin American Patients with Chronic Lymphocytic Leukemia: A Study By the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Does Prompt Access to Healthcare Impact the Outcomes of Hodgkin Lymphoma? a Comparison between Public and Private Patients Sharing the Same Infrastructure

Updated Analysis Confirms Sustained Poor Prognosis of COVID-19 in Patients with Lymphoma in Latin America: A Cohort of 160 Patients from Gell

Biological and Classical Prognostic Factors with Impact on Overall Survival in Patients with Early Stage (I/II) Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

PET-CT Quantitative Parameter Delta Suvmax As a Predictor of Early Relapse in Patients with Difuse Large B-Cell Lymphoma

Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

A Simplified Novel Prognostic Score to Predict Early Mortality and Disease Progression in Patients with Aggressive Adult T-Cell Leukemia/Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only